DiaMedica Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 41.51K shares, a 37.92% decline year-over-year.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 140.14K shares, a 278.75% increase year-over-year.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 171.25K shares, a 151.84% increase year-over-year.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 66.88K shares.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 117.00K shares.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 40.00K shares, a 180.05% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 41.51K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | |
| 2026-03-31 | 140.14K shares 10-Q · filed 2026-05-06 | |
| 2025-09-30 | 171.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 321.38K shares derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | 66.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 218.13K shares derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | 37.00K shares 10-Q · filed 2026-05-06 | |
| 2024-12-31 | 46.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | 117.00K shares 10-K · filed 2025-03-17 |
| 2024-09-30 | 68.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2023-12-31 | 0.00 shares 10-K · filed 2025-03-17 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 0.00 shares 10-K · filed 2024-03-19 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 0.00 shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 0.00 shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2023-05-15 | 0.00 shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | 40.00K shares 10-K · filed 2023-03-28 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 47.08K shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | 47.08K shares derived: sum of 4 quarters · filed 2022-03-14 |
| 2021-03-31 | 40.00K shares 10-Q · filed 2021-05-05 | 47.08K shares derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-12-31 | 7.08K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | 14.28K shares 10-K · filed 2022-03-14 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | |
| 2020-03-31 | 7.20K shares 10-Q · filed 2021-05-05 | |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | 16.95K shares 10-K · filed 2020-03-23 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | |
| 2017-12-31 | 3.00K shares 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |